

Factorial vs MAMS designs in clinical trials

25 September 2018 Despina Vasileiou



Outline



- Motivation and example
- Key design features
- Simulation results for different scenarios
- Case study design comparison
- Conclusions

Design comparison Motivation



- The FDA call for clinical trial methods that achieved reliable results more quickly necessitates both:
 - Simultaneous study of two or more treatments within one trial.
 - Accurate estimation of the main treatment effects.
- Designs commonly used in the literature.
 - Factorial designs, which include sole treatments and their combinations.
 - Multi-Arm designs (MA).
 - Multi-Arm Multi-Stage designs (MAMS).

Common design basis



- Comparing two arms, A and B, and their combination, AB, against control
- Normally distributed response, Y_j ~ N(μ_j, σ²) with *j* = A, B, AB, 0 and μ_j the mean effect of the response to treatment or control
- Global null hypothesis testing with overall type-I error control: $H_0 = \{H_{0A} : \mu_A \le \mu_0, \ H_{0B} : \mu_B \le \mu_0, \ H_{0AB} : \mu_{AB} \le \mu_0\}$
- Allocation ratios *r*, *q* for the single treatment and combination groups respectively, relative to the control group, *i.e* $n_A = n_B = rn_0$ and $n_{AB} = qn_0$, with comparisons based on balanced designs when r = q.

Multi-arm design features & Statistics University

• A four-arm design using Dunnett's test [2] uses the full model for treatment effect estimation.

 $Y_i = \beta_0 + \beta_1 \mathbf{I}_{Ai} + \beta_2 \mathbf{I}_{Bi} + \beta_3 \mathbf{I}_{Ai} \mathbf{I}_{Bi} + \varepsilon_i \text{ with } i = 1, 2, \dots, n_0 + n_A + n_B + n_{AB}$

(2)

Mean treatment response

Treatments		eatments	В		
			Presence	Absence	
	Α	Presence	$\beta_0 + \beta_1 + \beta_2 + \beta_3$	$\beta_0 + \beta_1$	
		Absence	$\beta_0 + \beta_2$	β_0	

• The statistics for the hypothesis testing are based on

$$Z_{\mathbf{c}_{j}^{\top}\boldsymbol{\beta}} = \frac{\mathbf{c}_{j}^{\top}\hat{\boldsymbol{\beta}}}{\sigma\sqrt{\mathbf{c}_{j}^{\top}(\boldsymbol{X}^{\top}\boldsymbol{X})^{-1}\mathbf{c}_{j}}}$$

Multi-arm multi-stage design features



- Extends Dunnett test to allow for interim analyses [3]
- Use of the O'Brien-Fleming boundary shape
- · Allows for early stopping based on benefit or lack thereof
- Selects treatments that look promising



Factorial design features Astatistics Lancaster Treatment effect and allocation impact

 Factorial designs assume no interaction in treatment effect estimation, *i.e.* β₃ = 0. In a 2 × 2 design:

$$Y_i = \beta_0 + \beta_1 \mathbf{I}_{Ai} + \beta_2 \mathbf{I}_{Bi} + \varepsilon_i$$

The test statistics used are

$$Z_{A} = \sqrt{n_{0}} \frac{r(r+q)(\bar{Y}_{A} - \bar{Y}_{0}) + qr(1+r)(\bar{Y}_{AB} - \bar{Y}_{B})}{\sigma\sqrt{(1+r)(r+q)(r^{2} + 2rq + r^{2}q)}}$$

$$Z_{B} = \sqrt{n_{0}} \frac{r(r+q)(\bar{Y}_{B} - \bar{Y}_{0}) + qr(1+r)(\bar{Y}_{AB} - \bar{Y}_{A})}{\sigma\sqrt{(1+r)(r+q)(r^{2} + 2rq + r^{2}q)}}$$

$$Z_{AB} = \sqrt{n_{0}} \frac{\bar{Y}_{AB} - \bar{Y}_{0}}{\sigma\sqrt{\frac{1+q}{q}}}$$
(3)

Factorial design features Allocation impact on critical values ($\alpha = 0.05$)

- Balanced design the critical value is found to be k = 2.028
- When r = q optimal which corresponds to critical value 2.017 is for r = q = 1.7
- For $r \in [0.5, 2.5]$ the optimum critical value of 1.954 occurs for q = 0.8, r = 2.5



r ∖q	0.1	0.5	1
0.1	2.09	2.10	2.11
0.5	2.07	2.05	2.07
1	2.06	2.02	2.03
2	2.04	1.97	1.98

Alternative scenarios Allocation impact on sample size



- Alternative hypothesis scenarios consistent with factorial design assumptions with $\Delta=0.5$ and $\delta_0=0.1$
 - 1. $H_1: \mu_A \mu_0 = \Delta, \mu_B \mu_0 = \delta_0, \mu_{AB} \mu_0 = \Delta + \delta_0, \mu_0 = 0$
 - 2. H₁: $\mu_A \mu_0 = \mu_B \mu_0 = \delta_0$, $\mu_{AB} \mu_0 = 2\delta_0$



- H_1 on the left: Balanced design sample size 160 with minimum 129 when r = 0.01 and q = 0.9
- H_1 on the right: Balanced design sample size 2008 with minimum 1150 when r = 0.01 and q = 1

Alternative scenarios Allocation impact on sample size

Alternative hypothesis scenarios inconsistent with factorial design assumptions with Δ = 0.5 and δ₀ = 0.1
 1. H₁: μ_A - μ₀ = Δ & μ_B - μ₀ = μ_{AB} - μ₀ = δ₀

Mathematics & Statistics University

- 1. $H_1: \mu_A \mu_0 = \Delta \& \mu_B \mu_0 = \mu_{AB} \mu_0 = \delta_0$
- 2. $H_1: \mu_{AB} \mu_0 = \Delta, \mu_A \mu_0 = \mu_B \mu_0 = \delta_0$



- H_1 on the left: Balanced design sample size 704 with minimum 326 when r = 0.81 and q = 0.1
- H₁ on the right : Balanced design sample size 324 with minimum 199 when r = 0.1 and q = 1

Simulation Results



Effect of interaction on factorial designs

- Explore additivity of treatment effects in balanced designs
- β_3 , ranges from -1 to 1 (antagonism to synergy)



For H_1 : { H_{1A} : $\mu_A > 0$, or H_{1B} : $\mu_B > 0$, or H_{1AB} : $\mu_{AB} > 0$ }, and for the remaining three plots H_{1j} : $\mu_j > 0$ for each j = A, B, AB.

Comparison Results



Direct power comparison between all designs

- Based on study evaluating use of physiotherapy on osteoarthritis [1]
- Either manual physiotherapy, exercise physiotherapy, both or standard of care
- n = 45 per group
- Difference in points of WOMAC score
- Interesting effect $\Delta = 28$, uninteresting $\delta_0 = 7$ and $\sigma = 50$.
- Performance of Factorial, MA and MAMS designs

Comparison Results



Probability of rejecting the null hypothesis



0:
$$\mu_0 = \mu_A = \mu_B = \mu_{AB} = 0$$

i: $\mu_A - \mu_0 = \Delta$,
 $\mu_B - \mu_0 = \mu_{AB} - \mu_0 = \delta_0$
ii: $\mu_A - \mu_0 = \mu_B - \mu_0 = \delta_0$,
 $\mu_{AB} - \mu_0 = \Delta$
iii: $\mu_A - \mu_0 = \Delta$, $\mu_B - \mu_0 = \delta_0$,
 $\mu_{AB} - \mu_0 = \Delta + \delta_0$
iv: $\mu_A - \mu_0 = \delta_0$, $\mu_B - \mu_0 = \delta_0$,
 $\mu_{AB} - \mu_0 = 2\delta_0$

Interaction effect



Probability of rejecting the null hypothesis, while the interaction ranges from -2 to 2 (* Δ) when:

1.
$$\mu_A - \mu_0 = \mu_B - \mu_0 = 0$$

2. $\mu_A - \mu_0 = \mu_B - \mu_0 = 7$
3. $\mu_A - \mu_0 = 0 \& \mu_B - \mu_0 = 28$



Red for factorial design, black for MA design and green for MAMS design

Design differences Total sample size



Comparison amongst sample sizes of a balanced factorial design, a multi-arm design and the expected sample size of a multi-arm two-stage design with 0 futility boundary using case study parameters and $\alpha = 0.05$, $1 - \beta = 0.9$.







- No difference in the expected sample size of a MAMS trial and a factorial one when there is no interaction between the treatments.
- Observed a notable inflation of the type I error in the simulation study when the sole treatments interact in a synergistic manner (β₃ > 0).
- Also found losses of power when the treatments have in combination an antagonistic effect.
- Factorial designs should only be considered instead of a multi-arm design when there is evidence that the assumption of additivity is met.
- MAMS designs are a robust alternative to the presence of interactions and are expected to require a much smaller sample size at the expense of a small deficiency in power.

References





J. H. Abbott, M. C. Robertson, J. E. McKenzie, G. D. Baxter, J.-C. Theis, A. J. Campbell, et al.

Exercise therapy, manual therapy, or both, for osteoarthritis of the hip or knee: a factorial randomised controlled trial protocol.

Trials, 10(11):6215-10, 2009.



C. W. Dunnett.

Selection of the best treatment in comparison to a control with an application to a medical trial. *Design of experiments: Ranking and selection*, pages 47–66, 1984.



D. Magirr, T. Jaki, and J. Whitehead.

A generalized dunnett test for multi-arm multi-stage clinical studies with treatment selection. *Biometrika*, 99(2):494–501, 2012.

Published Paper



Jaki, T. and Vasileiou, D.

Factorial versus multiarm multistage designs for clinical trials with multiple treatments. *Statistics in medicine*, 36(4), pp.563-580,2017.





25 September 2018 Despina Vasileiou

